secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIPELLA PHARMACEUTICALS INC. (LIPO)
CIK:        0001347242
Form:       8-K
Filed at:   2024-08-23T23:59:59+00:00
Accession:  0001753926-24-001473
Event type: regulatory
Sentiment:  negative
Materiality: 0.70
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Lipella receives Nasdaq delisting notice; equity $1.7M vs $2.5M minimum
-----------------------------------------------------------------------

- Nasdaq notified Lipella on Aug 21, 2024 of non-compliance with $2.5M minimum stockholders' equity requirement.
- Company reported stockholders' equity of $1,703,798 in Q2 10-Q, below the $2.5M threshold.
- Company must submit compliance plan by Oct 7, 2024; intends to do so.
- If plan accepted, Nasdaq may grant up to 180-day extension from Aug 21, 2024.
- Failure to regain compliance could result in delisting of LIPO common stock.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1347242/000175392624001473/0001753926-24-001473-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1347242/000175392624001473/g084405_8k.htm
  HTML page:      https://secwatch.observer/filing/0001753926-24-001473

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer